Aims Tobacco smoking is known to increase the long-term risk of developing Type 2 diabetes mellitus, but the mechanisms involved are poorly understood. This observational, cross-sectional study aims to compare measures of insulin sensitivity and b-cell function in current, ex-and never-smokers.
Introduction
Tobacco smoking is known to increase the long-term risk of developing Type 2 diabetes mellitus [1, 2] . A recent study showed an association between smoking and incident Type 2 diabetes after full adjustment for educational level, physical activity, diet and alcohol consumption, suggesting a causal relationship [3] . Meta-analyses have also demonstrated Type 2 diabetes to be associated with passive tobacco smoking [2, 4] .
If smoking does indeed increase the risk of Type 2 diabetes, the underlying mechanisms are not clear, but might include changes in insulin sensitivity, insulin secretion or a combination of both. Although smokers are known to have a lower BMI than non-smokers, they tend to exhibit a different body composition with an abdominal fat accumulation [5] . Previous studies have shown increased insulin resistance among smokers compared with non-smokers [6] and that smoking cessation improves insulin sensitivity [7] , although other studies have shown no such associations [8] [9] [10] [11] [12] . Smoking might also cause diabetes by damaging pancreatic b-cells, but conflicting results have been published regarding Correspondence to: Mikael Gotts€ ater. E-mail: mikael.gottsater@med.lu.se ª 2016 Diabetes UK impaired insulin secretion among smokers and non-smokers [8, 9, 12] .
The aim of this cross-sectional study was to investigate insulin resistance and b-cell function, as well as glucose, insulin and C-peptide levels during the oral glucose tolerance test (OGTT), among current smokers, ex-smokers and never smokers in a healthy, European population without diabetes.
Study population and methods
The study population is part of the EGIR-RISC database of men and women, aged 29-63 years, from 19 centres in 14 European countries, who were investigated from 2002 to 2004 [13] . The EGIR-RISC study aimed to investigate the relation between insulin sensitivity and atherosclerosis. All participants gave written informed consent prior to study inclusion and ethical approvals were obtained from the respective local ethics committee. The participants were all health-selected and individuals with treatment for diabetes, hypertension, dyslipidaemia or cardiovascular disease were excluded. Moreover, individuals with any of these conditions at the study examination were also excluded. A more detailed list of exclusion criteria has been published previously [13] . Data on smoking habits, alcohol consumption, family history of diabetes and physical activity were retrieved from a questionnaire. Smoking status was self-reported and defined as current, ex-or never smoker. Alcohol consumption was dichotomized into high and low consumption. A high alcohol intake was defined as a weekly consumption of > 168 g of pure alcohol for men and > 108 g for women, cut-off values for harmful effects of alcohol used by several national health institutes [14, 15] . Physical activity was assessed with the International Physical Activity Questionnaire (IPAQ), a validated instrument for measuring physical activity in adults [16] .
Insulin sensitivity was measured by the hyperinsulinaemic, euglycaemic clamp in 1319 individuals [13] . The target plasma glucose concentration was between 4.5 and 5.5 mmol/l. Insulin infusion rate was 240 pmol/min/m. Plasma or blood glucose was measured at the bedside every 5-10 min to ensure it remained within 0.8 mmol/l (AE 15%) of the target glucose concentration. The steady-state period (for calculation of insulin sensitivity) was between 80 and 120 min. Additionally, an OGTT was performed with a standard 75 g glucose monohydrate solution.
The study population was reduced from the original 1319 individuals to 1199 individuals due to missing values for key variables and because some individuals met the exclusion criteria (Fig. 1) . The characteristics of the final study population of 1199 individuals are presented in Table 1 . The study population (n = 1199), when compared with the excluded population (n = 120), had significantly lower BMI (25.4 vs. 26.4 kg/m 2 , P = 0.03) and a lower percentage of high-alcohol consumers (8% vs 16%, P = 0.01). For the other variables listed in Table 1 (age, sex, waist circumference, fasting glucose and physical activity) there were no statistically significant differences. Furthermore for each variable studied, data from a few additional individuals were missing, presented in Table 2 .
Insulin sensitivity was calculated as M/I (lmol 9 min À1 9 kg ffm À1 9 nM À1 ) from clamp data, where M is the glucose infusion rate during the last 40 min of the 120 min clamp, normalized by the fat-free-mass and I is the mean plasma insulin concentration during the same time interval [17, 18] . Additionally, the homeostatic model assessment -insulin resistance (HOMA-IR) was calculated as described by Matthews et al. [19] using the formula: (fasting insulin 9 fasting glucose)/22.5, where insulin is expressed as mIU/l and glucose as mmol/l. The rationale for using HOMA-IR in addition to clamp data was to assess insulin sensitivity in a physiological setting more similar to the glucose load following a meal, as well as to facilitate the comparison with previous studies not using a clamp measure of insulin sensitivity. Two separate measurements of b-cell function were calculated from the OGTT. The early insulin response index (EIRI), the ratio of the increment in insulin concentration during the first 30 min of an OGTT to the glucose concentration at 30 min (Δinsulin 30 min/glucose 30 min) [20] . EIRI is a measurement of the early phases of insulin secretion and it has been described as a physiological estimation. b-Cell glucose sensitivity is described by Mari et al. [21, 22] . Glucose sensitivity is the slope of the dose-response curve and reflects the sensitivity of the b-cell to changes in plasma glucose levels after the initial rise in glucose following an OGTT.
The areas under the curves (AUC) during the OGTT were calculated for glucose, insulin and C-peptide, to compare levels during all of the OGTT, rather than just at specific time points.
Descriptive data are presented as mean AE SD or %, stratified according to sex and smoking status.
The differences in insulin sensitivity, b-cell function and AUC measurements between smoking groups were analysed with analysis of variance (ANOVA) including Levene's test of equality of variances and in case of significant differences the P-value from the Welch test was used. Analyses were then adjusted for age and study centre with analysis of covariance (ANCOVA). Further adjustments were made for BMI, family history of diabetes, physical activity and alcohol
What's new?
• Smoking is not associated with insulin sensitivity or bcell function in healthy participants, in this large study with insulin sensitivity measured using hyperinsulinaemic, euglycaemic clamps.
• Smoking is associated with increased glycaemic and Cpeptide responses during an oral glucose tolerance test.
consumption. Indices of b-cell function were also adjusted for insulin sensitivity (M/I). All analyses were stratified by gender. M/I, EIRI, GS, BMI, IPAQ score and insulin AUC were transformed by logarithms to achieve more symmetrical distributions. Statistical differences in glucose and C-peptide levels at each time point during the OGTT were compared with the Mann-Whitney U-test, between current smokers and the combination of ex-smokers and never smokers.
A P-value of < 0.05 was considered significant.
Results
In all, 26.5% were current smokers, 27.4% ex-smokers and 46.1% never smokers. The study population was aged between 29 and 61 years, with a mean age of 44 years, and 55% were women (Table 1) . In women, M/I differed significantly between smoking groups (P = 0.03) and was higher in smokers in an unadjusted model (Table 2 ). In men, there were significant differences (P = 0.04) in glucose sensitivity between smoking categories in unadjusted models. In fully adjusted models, no significant differences remained for M/I, HOMA-IR, EIRI or glucose sensitivity for either sex.
In men, after full adjustment in Model 2, there were differences between smoking groups for glucose AUC (P = 0.02) and for C-peptide AUC (P = 0.005), with smokers showing higher levels ( Table 2 ). In women, the AUC of C-peptide was highest among ex-smokers, but similar to current smokers, with a significant (P = 0.03) difference between the three groups after full adjustment.
The time curves of plasma glucose and C-peptide levels during the OGTT are presented for men and women, in Appendix S1. At 30 min (P = 0.04) and 60 min (P = 0.02) into the OGTT the corresponding glucose levels were significantly higher in men who smoked compared with those who had never smoked or were ex-smokers, in unadjusted analyses. For women, there were no such differences. There were no differences in C-peptide or insulin levels at any time point during OGTT.
Conclusion
Smokers are at higher risk of developing Type 2 diabetes [1, 3] . Because this process takes a long time, a cross-sectional analysis should be able to show either a contributing increased insulin resistance or decreased b-cell function in smokers without diabetes. In this health-selected allEuropean population, smokers did not show a decreased insulin sensitivity or b-cell function compared with exsmokers and never-smokers after adjustment.
Some previous studies have compared insulin sensitivity between smokers and non-smokers using clamp data in a similar way. In a small study including 40 men, it was shown that insulin sensitivity improved after 8 weeks in the 17 men who quit smoking compared with the remaining 23 participants [7] . However, several larger studies have investigated the relationship between smoking and insulin sensitivity using HOMA-IR [8, 9] , insulin at three time points during an OGTT [10] or an intravenous glucose tolerance test [11] , without showing any evidence of an increased insulin resistance in smokers.
Despite the absence of decreased insulin sensitivity or secretion in smokers, we found that male smokers showed an increased glucose and C-peptide AUC during the OGTT. The increased AUCs in smokers are due to a more rapid increase in glucose and C-peptide 30-90 min into the OGTT. Similar patterns have been previously reported in a study of 1454 men without diabetes, in whom blood glucose levels were higher in smokers 40 and 60 min into the OGTT, whereas no differences were observed at 0 or 120 min [23] . It has previously been shown in a small study including 20 smokers and 20 non-smokers, that the acute effect of smoking was a delayed insulin response during the OGTT [24] . The results are also consistent with results from a meta-analysis of 35 425 people without diabetes showing a higher HbA 1c in Table 2 Mean AE SD of insulin sensitivity, b-cell function and glucose, insulin and C-peptide area under the curve (AUC) during the oral glucose tolerance test (OGTT) according to sex and smoking categories: the EGIR-RISC Study smokers, while also reporting no differences in fasting glucose but a lower glucose 2 h after an OGTT [25] . We speculate that the increased plasma glucose and Cpeptide during the OGTT that we found in this study could be explained by small, early disturbances in glucose metabolism associated with smoking that are not detectable by the insulin sensitivity or secretion indices used in this study. Alternatively, the increased plasma glucose in smokers observed at 30 and 60 min into the OGTT might be due to faster gastric emptying as this has previously been described in abstaining smokers [26] . This would cause the glucose solution to reach the duodenum faster, resulting in a quicker glucose uptake.
A meta-analysis has shown that the increased risk of Type 2 diabetes associated with smoking is greater in men than in women [3] . Thus, the mechanisms behind the association between smoking and diabetes seem more evident in men, a fact that could explain the sex differences during the OGTT found in our study. This is, to our knowledge, the largest study to date using the gold standard clamp methodology to investigate insulin sensitivity in relation to smoking. This is a major strength. Smoking is well-known to be associated with other lifestyle-related factors that might influence insulin secretion or b-cell function. We chose to adjust for age and research centre to account for national and cultural differences. Otherwise, the lack of differences between smoking categories in our study could be interpreted as over-adjustment. It is unlikely that lack of adjustment caused the absence of significant results in this study.
The crude division of the population into three smoking categories, with no information on pack-years of smoking exposure, limits the ability to measure associations between exposure and outcome.
In conclusion, in a health-selected European population without diabetes, smokers did not show evidence of decreased insulin sensitivity or b-cell function compared with ex-smokers and never-smokers. However, increased glycaemic and C-peptide responses were evident in male smokers following an OGTT, a finding that needs to be evaluated further.
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